Litcius/Paper detail

Clinical assessment of SARS-CoV-2 antigen rapid detection compared with RT-PCR assay for emerging variants at a high-throughput community testing site in Taiwan

Ming‐Jr Jian, Cherng‐Lih Perng, Hsing‐Yi Chung, Chih-Kai Chang, Jung‐Chung Lin, Kuo‐Ming Yeh, Chien‐Wen Chen, Shan‐Shan Hsieh, Pin-Ching Pan, Hao-Ting Chang, Feng‐Yee Chang, Ching‐Liang Ho, Hung‐Sheng Shang

2021International Journal of Infectious Diseases30 citationsDOIOpen Access PDF

Abstract

OBJECTIVES: With the emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) B.1.1.7 lineage in the ongoing coronavirus disease 2019 (COVID-19) pandemic, Taiwan confronted a COVID-19 flare up in May 2021. Large-scale, accurate, affordable and rapid diagnostic tests such as the lateral flow assay can help to prevent community transmission, but their performance characteristics in real-world conditions and relevant subpopulations remain unclear. METHODS: The COVID-19 Antigen Rapid Test Kit (Eternal Materials, New Taipei City, Taiwan) was used in a high-throughput community testing site; the paired reverse transcription polymerase chain reaction (RT-PCR) results served as a reference for sensitivity and specificity calculations. RESULTS: Of 2096 specimens tested using the rapid antigen test, 70 (3.33%) were positive and 2026 (96.7%) were negative. This clinical performance was compared with the RT-PCR results. The sensitivity and specificity of the rapid antigen test were 76.39% [95% confidence interval (CI) 64.91-85.60%] and 99.26% (95% CI 98.78-99.58%), respectively, with high sensitivity in subjects with cycle threshold values ≤24. Further, the rapid antigen test detected the SARS-CoV-2 B.1.1.7 lineage effectively. CONCLUSIONS: Considering the short turnaround times and lower costs, this simple SARS-CoV-2 antigen detection test for rapid screening combined with RT-PCR as a double confirmatory screening tool can facilitate the prevention of community transmission during COVID-19 emergencies.

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntigenMedicineConfidence intervalCoronavirus disease 2019 (COVID-19)VirologyReal-time polymerase chain reactionPolymerase chain reactionReverse transcription polymerase chain reactionTransmission (telecommunications)Turnaround timeImmunologyBiologyInternal medicineDiseaseGeneInfectious disease (medical specialty)GeneticsComputer scienceMessenger RNAOperating systemTelecommunicationsSARS-CoV-2 detection and testingSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies